What is CVR? The mysterious bet in mergers and acquisitions.

In large mergers and acquisitions, there is often a strange thing called CVR (Contingent Value Right) - which translates to "conditional value right". In simple terms, it means:

If an event occurs within the specified time, you will receive money; if it does not occur, you will not receive a penny.

Sounds like options, right? It's pretty much the same.

Why does this exist?

Most CVRs appear in biopharmaceutical mergers and acquisitions. Imagine this scenario: the acquirer does not want to spend more money on a new drug that is not yet on the market and carries high risks, while the target company wants to prove that it is worth that price. What to do? Just create a CVR - if the drug is approved in the future or if sales reach a certain amount, the shareholders of the target company can receive extra money.

In the famous deal in 2011 when Sanofi acquired Genzyme, it was done like this: $74 per share + 1 CVR, with the CVR potentially worth an additional $14 (if all milestones are achieved).

Can it make money?

If CVR can be traded (listed on an exchange), then there is hope. You don't need to hold the original company's stock, and you can buy and sell CVR separately. The price will fluctuate based on the market's perception of "the probability of this drug being approved." It's akin to betting directly on a merger event at a low price.

But most CVRs are actually non-tradable, and can only be passively obtained when the merger is completed, then you just wait (possibly for several years) to see if there are any dividends.

Where is the risk?

First of all, each CVR is a customized product, with terms varying widely—some require FDA approval, some require sales targets, and some even have multiple milestones. You must thoroughly understand the SEC documents before placing your bets.

Secondly, it may be worth nothing. Just like options, if the drug is not approved or sales do not meet the standards, the CVR will expire, leaving you with a worthless piece of paper.

Finally, there is a hidden danger: does the acquiring company truly intend to promote this project? Although the contract requires "good faith operation," if a product that they actually do not have confidence in is acquired just to complete the transaction, the subsequent investment in it will be insufficient. There is an inherent conflict of interest between CVR holders and the acquiring company.

In simple terms: CVR is a wager in mergers and acquisitions, with decent odds, but you need to carefully understand the terms before placing your bet.